Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Hyderabad, India September 2, 2021 and Mississauga, ON, CAN. September 1, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.

Read the Full Release

Member Forum 2025

September 9, 2025
Angus Glen Golf Club, South Course
Markham, Ontario

MORE INFO

Boot Camp 2025

November 18 - 19, 2025
Online Event

MORE INFO

Executive Conference 2026

January 12 - 13, 2026
Montreal Airport Marriott In-Terminal Hotel
Dorval, QC H4Y 0A4

MORE INFO

Annual Conference 2026

May 3 - 6, 2026
Hotel Monteleone
New Orleans, Louisiana, United States

MORE INFO